financetom
Business
financetom
/
Business
/
Costco Q4 Earnings: Revenue Miss, EPS Beat, Comps Climb 5.4%, Shares Slide
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Costco Q4 Earnings: Revenue Miss, EPS Beat, Comps Climb 5.4%, Shares Slide
Oct 3, 2024 1:52 AM

Costco Wholesale Corp ( COST ) reported fourth-quarter financial results after the market close on Thursday. Here’s a look at the key numbers from the quarter.

Q4 Earnings: Costco reported fourth-quarter revenue of $79.697 billion, missing the consensus estimate of $79.973 billion. The membership-based retailer reported quarterly earnings of $5.29 per share, beating analyst estimates of $5.08 per share, according to Benzinga Pro.

Comparable sales in the fourth quarter were up 5.3% in the U.S., up 5.5% in Canada and up 5.7% in the Other International segment. Total comps climbed 5.4% year-over-year, and total e-commerce sales jumped 18.9%. The reported figures were adjusted to account for the total weeks in the quarter.

Costco’s fourth quarter this year was a 16-week period versus 17 weeks in the fourth quarter of 2023.

Membership fees came in at $1.512 billion, up from $1.509 billion in the prior year’s quarter. Costco announced it was raising the price of its annual store membership by $5 in July. The membership fee increase went into effect on Sept. 1.

Costco noted it now operates 891 warehouses. The company said it ended the quarter with $9.906 billion in cash and cash equivalents.

Management will hold a conference call with investors and analysts to discuss these results at 5 p.m. ET.

Related Link: Top 10 Stock Picks For The Holiday Boom: Adobe Forecasts Unprecedented E-Commerce Sales This Season

COST Price Action: Costco shares were down 1.10% in after hours, trading around $891.50 at the time of publication Thursday, per Benzinga Pro.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Incyte Q3 Non-GAAP Earnings, Revenue Increase
Incyte Q3 Non-GAAP Earnings, Revenue Increase
Oct 28, 2025
07:28 AM EDT, 10/28/2025 (MT Newswires) -- Incyte ( INCY ) reported Q3 non-GAAP earnings Tuesday of $2.26 per diluted share, up from $1.07 a year earlier. Analysts polled by FactSet expected $1.58. Revenue for the quarter ended Sept. 30 was $1.37 billion, up from $1.14 billion a year earlier. Analysts surveyed by FactSet expected $1.25 billion. ...
Barclays to Acquire Leading U.S. Personal Loan Originator Best Egg
Barclays to Acquire Leading U.S. Personal Loan Originator Best Egg
Oct 28, 2025
WILMINGTON, Del., Oct. 28, 2025 /PRNewswire/ -- Barclays PLC (Barclays)1 today announces that its wholly-owned US consumer banking subsidiary Barclays Bank Delaware (operating as Barclays US Consumer Bank or USCB) has agreed to acquire Best Egg, Inc. (Best Egg or the Business)2 for $800 million3 (the Transaction). Completion of the Transaction (Completion) is subject to required regulatory approvals and other conditions....
Trump says he will meet Nvidia CEO on Wednesday
Trump says he will meet Nvidia CEO on Wednesday
Oct 28, 2025
TOKYO, Oct 28 (Reuters) - U.S. President Donald Trump said he would meet with Nvidia ( NVDA ) Chief Executive Jensen Huang on Wednesday. Trump made the comment Tuesday in an address to business leaders in Tokyo before traveling to South Korea. The U.S. AI chipmaker said last week that Huang plans to meet global leaders and top Korean executives...
Regeneron beats quarterly estimates on strong demand for Dupixent
Regeneron beats quarterly estimates on strong demand for Dupixent
Oct 28, 2025
Oct 28 (Reuters) - Regeneron Pharmaceuticals ( REGN ) beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its eczema treatment, Dupixent, and cancer treatment Libtayo, sending its shares up 5.6% premarket. Analysts said Dupixent, made by the U.S. drugmaker in partnership with Sanofi, continues to impress, after the drug topped quarterly sales expectations when...
Copyright 2023-2026 - www.financetom.com All Rights Reserved